Santen gets approval of TAPROS in China to treat open-angle glaucoma and ocular hypertension
TAPROS is the Prostaglandin F2a Analogue co-developed by Santen and Asahi Glass Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo) for the reduction of intraocular pressure (IOP) in glaucoma and ocular
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.